Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
life sciences
national blog main
new york blog main
agios pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boston
cancer
cancer drugs
david e. shaw
drug discovery
duchenne muscular dystrophy
dyne therapeutics
enasidenib
facioscapulohumeral muscular dystrophy
fda
gene therapy
investing
ipo
ivosidenib
joshua brumm
kaleido biosciences
materials science
morphic
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york
new york top stories
nimbus therapeutics
rare disease drugs
romesh subramanian
san diego blog main
What
experimental
2
×
ipo
2
×
medicines
ago
biotechs
company’s
considering
course
data
development
discover
diseases
drug
dyne
early
expected
eyes
genetic
growing
handiwork
having
helped
humans
internal
ipos
landscape
long
muscle
pipeline
rare
reach
scan
schrödinger
schrödinger’s
sets
software
spot
support
therapeutics
today
Language
unset
Current search:
ipo
×
experimental
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
